Jefferies cuts STAAR Surgical stock price target on estimate update
Jefferies cut its price target for STAAR Surgical (STAA) to $28 from $29 but kept a Hold rating after the company’s Q2 2026 results. Revenue was $93.5M, flat QoQ and 4% above consensus. China sales were $52.3M. Gross margin was 74.5%, but EPS was $0.16 vs $0.22 consensus.
How this was made
The 30-second read
Why it matters
For traders, the key decision input is the PT reduction ($28 vs $29) alongside mixed fundamentals: revenue and margins beat, but EPS missed and there is no formal guidance.
Market read
This is a single-name sell-side adjustment after Q2, with mixed earnings quality (revenue and margins up, EPS down) and no formal guidance.
What to watch
The article notes no formal guidance; traders may focus more on management’s second-half commentary details (not provided here) and on whether the estimate update reflects temporary timing versus durable demand.
Background
The piece centers on Jefferies’ post-Q2 estimate update for STAAR Surgical, including a PT trim and a Hold rating.
Ticker impact
Jefferies cut STAAR Surgical’s price target to $28 from $29 while keeping a Hold rating after Q2 results and estimate updates.
Near-term downside bias from the PT cut, partially offset by revenue and margin outperformance.
The article’s actionable change is the PT reduction tied to updated estimates; it also highlights EPS miss versus consensus and lack of formal guidance, which can cap upside despite strong China sales and gross margin.
Market effects
Limited read-through to ophthalmic/medical device peers since the catalyst is a single-name analyst estimate update.
China sales growth is a positive regional signal, but the article does not imply broader China demand changes.
No direct global macro or regulatory spillover beyond the single analyst action.
Counterpoint
Despite the EPS miss, the combination of gross margin and EBITDA margin beats plus sequential China growth could mean the Hold/PT cut is conservative rather than a fundamental deterioration.
Key entities
- companySTAAR Surgical
NASDAQ-listed medical device company whose Q2 2026 results prompted Jefferies to lower its price target while maintaining a Hold rating.
- analyst_firmJefferies
Issued the price target cut and maintained the Hold rating after updating estimates post-quarter.
